

Product Focus

Pharmaceutical Distribution

Market disruption/supply issue

April 10, 2020

Ranitidine product update

On April 1, 2020, the U.S. Food and Drug Administration released a [Press Announcement](#) requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. With the announcement, the FDA is sending letters to all manufacturers of ranitidine requesting they withdraw their products from the market. The FDA is also advising consumers taking OTC ranitidine to stop taking any tablets or liquid they currently have, dispose of them properly and not buy more.

Cardinal Health has stopped distribution of all ranitidine products and will communicate any official withdrawal notices and instructions from manufacturers as they are received.

As a pharmaceutical distributor, Cardinal Health does not make clinical recommendations and is not in a position to recommend alternative products that meet your individual patient's health needs. As a licensed healthcare professional, you are solely responsible to determine when and if an alternative product is appropriate for the treatment of a patient.

